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Abstract Coronary heart disease (CHD) and depression are
both highly prevalent in women. Importantly, depression is
associated with significantly elevated morbidity and mortality in women with CHD. There are intriguing speculations
about biological mechanisms underlying this association,
such as endothelial dysfunction, subclinical atherosclerosis,
inflammation, and autonomic dysregulation. Social and behavioral mechanisms, such as lack of social support and
physical inactivity, have also been shown to play important
roles. Unfortunately, many randomized clinical trials of
counseling and pharmacologic interventions for depression
in patients with CHD have failed to improve cardiovascular
outcomes, and in fact have raised the possibility that interventions might be harmful in women. Several recent trials of
new treatment strategies, however, have been more effective
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in improving depressive symptoms and quality of life and
deserve further investigation. In this review, we summarize
recent findings with regards to the epidemiology, etiology,
diagnosis, and management of depression in women diagnosed with CHD.
Keywords Depression . Women . Epidemiology .
Management . Coronary heart disease

Introduction
Despite advances in prevention and treatment, cardiovascular disease (CVD) remains the leading cause of death for
women in the United States, accounting for>300,000 deaths
per year [1]. Depression is common in patients with CHD:
around 20% meet criteria for major depression, and up to
50% experience some depressive symptoms [2]. Furthermore, depression has been shown to be independently associated with significantly increased risk for recurrent
cardiovascular events and mortality [2, 3]. Similar to the
general population, women with CHD are much more likely
to experience depression as compared to men, and it has
been argued that this partly explains why women face increased risk of death after myocardial infarction (MI) [4].
Due to these considerations, depression screening and treatment for patients with CHD has been recommended by both
the 2008 American Heart Association (AHA) Science Advisory on Depression and Heart Disease [5••] and the 2011
update of the AHA Practice Guidelines for Prevention of
Cardiovascular Disease in Women [6]. To date, however,
depression interventions have demonstrated only limited
cardiovascular or mental health benefits in patients with
CHD [7, 8••].
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Currently, the relationship between depression and cardiovascular risk remains an area of active investigation. In this
review, we highlight recent literature on the prevalence and
impact of depression in this patient population, the mechanisms
that could potentially explain the elevated risk conferred by
depression, as well as the ongoing debate on how best to
diagnose and manage depression in women with CHD.

Prevalence and Impact
The association between depression and increased risk for
incident CHD events was confirmed by several large cohort
studies, though there was mixed evidence on whether women
might be at higher risk than men. Because there were considerable variations in these studies on how depressive symptoms
were assessed, the specific instrument used for each will be
briefly mentioned. Nabi et al. [9] reported that in a Finnish
cohort of 23,282 young to middle-aged adults (59% women)
with no prior CHD, presence of elevated depressive symptoms, defined as Beck Depression Inventory (BDI) score≥10
(hazard ratio [HR] 1.47, 95% CI 1.08–1.99) or being prescribed anti-depressants, were independent risk factors for
developing incident CHD (HR 1.72, 95% CI 1.06–2.77) [9].
Similarly, in a cohort of 2278 urban adults aged 60 years or
older without prior cardiovascular disease (CVD), of which
71% were women, depressive symptoms as measured by the
Center for Epidemiologic Depression Scale (CES-D) score≥
16 were associated with a nearly 50% increase in the risk of
incident myocardial infarction (MI) or CHD death (relative
risk [RR] 1.46, 95% CI 1.20–1.77) after adjustment for demographic and medical covariates [10]. In both studies, tests
of interaction did not show any differences between men and
women in the strength of association between depression and
cardiac risk. In contrast, Shah et al. [11] found that in 7641 US
adults (54% women) younger than 40 years of age, depression
or a history of attempted suicide as assessed via the Diagnostic
Interview Schedule was associated with increased risk of
premature death from CVD and ischemic heart disease
(IHD), with the effect size more pronounced in women compared to men (for CVD, HR 3.20, 95% CI 1.12–9.17 for
women vs HR 2.37, 95% CI 0.85–6.58 for men; for IHD,
HR 14.57, 95% CI 2.65–80.10 for women vs HR 3.52, 95%
CI 1.05–11.76 for men). Although these results are intriguing,
it should be noted that the absolute incidence of events were
low in this study, resulting in wide confidence intervals [11].
Several studies have further refined our understanding of
how depression adversely affects the prognosis of patients
with CHD. The Heart and Soul Study followed 1017 patients
(18% women) with stable CHD and reported that elevated
depressive symptoms, defined as Patient Health Questionnaire
(PHQ-9) score≥10, were associated with increased risk for
subsequent cardiovascular events (HR 1.50, 95% CI 1.16–
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1.95) [12•]. An innovative case–control study by Larsen et al.
[13] using a large Finnish registry showed that patients after
MI are at higher risk for suicide, the most extreme manifestation of depression. The risk was especially pronounced in
those who had previous psychiatric illnesses (RR 64.05,
95% CI 13.36–307.06), but was also elevated in those who
did not (RR 3.25, 95% CI 1.61–6.56) [13]. In this study, male
and female patients had similar risk of suicide following MI.
Further highlighting the complexity of the relationship between depression and outcomes in patients with CHD, another
study examined whether the dynamic course of depressive
symptoms following CHD diagnosis influences cardiac risk.
In a cohort of 2325 patients (31% women) with stable CHD,
Doering et al. [14] assessed persistent symptoms of depression
and anxiety across a 3-month period using the Multiple Adjective Affect Checklist. The combination of both was present
in 26% of participants, and was furthermore associated with
increased mortality (odds ratio [OR] 2.35, 95% CI 1.23–4.47).
Notably, women were also more likely to have combined
persistent depression and anxiety symptoms (30.6% vs
24.2% for males, P00.001) [14]. These results are consistent
with the emerging understanding that the relationship between
depression and elevated cardiovascular risk may be modified
by what is now termed “depression phenotypes” (eg, persistent
depression or mixed depression/anxiety) [15•].
Finally, the potential increase in healthcare costs for women with depression and CHD was formally evaluated in the
Women’s Ischemia Syndrome Evaluation Study. Accounting
for both direct costs of healthcare utilization and indirect costs
such as loss of productivity, those with depression (defined by
either use of anti-depressants, self-reported depression treatment, or baseline BDI score≥10) incurred annual costs that
were on average $1550 to $3300 higher than those without
depression [16]. Higher costs associated with depression were
seen in women with and without angiographic evidence of
CHD, though the association was only significant in the latter.
These findings will be useful for cost-effectiveness evaluations
of future depression interventions.

Potential Mechanisms
A variety of biological, social, and behavioral mechanisms
have been invoked to explain the association between depression and cardiovascular outcomes. The most relevant
findings that apply to women with CHD and depression are
summarized below.
Biological Mechanisms
As a whole, recent investigations of biological mechanisms
underlying the relationship between depression and CHD risk
tended to show negative or mixed results. Of the studies that
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examined the role played by endothelial dysfunction, a metaanalysis by Cooper et al. [17] found that both clinical and
subclinical depression was modestly associated with impaired
flow-mediated dilatation (r00.19, 95% CI 0.08–0.29). Women were well-represented in the individual studies, and the
correlation was larger when restricted to studies of patients
with CHD or CHD risk factors (r00.29). However, in another
study of 434 urban subjects (55% women), depressive symptoms as measured by CES-D were not associated with serum
markers of endothelial function, including e- and p-selectins
and s-ICAM1 [18]. Similarly, recent studies have challenged
the hypothesis that the risk associated with depression in
women with CHD can be explained by inflammatory processes. In a cross-sectional study of 9258 subjects (54% women),
Bjerkeset et al. [19] showed that depressive symptoms defined
as Hospital Anxiety and Depression Scale (HADS-D) score≥
8 were associated with elevated C-reactive protein (CRP) in
the unadjusted model (OR 1.28, 95% CI 1.10–1.49); however,
this association disappeared after full adjustment for prior
medical conditions and demographic and lifestyle covariates
(OR 1.08, 95% CI 0.91–1.30) [19]. Negative findings were
also reported by Amyre Morris et al. [20], who examined the
relationship between depression defined as BDI score≥14 and
elevated CRP level in a cohort of 512 African American and
white participants (61% women). In this study, the association
between depressive symptoms and elevated CRP disappeared
after adjusting for metabolic risk factors such as smoking
status, waist circumference, systolic blood pressure, and cholesterol [20], suggesting that these traditional risk factors
represent confounders of this relationship.
There were also mixed results with regards to the role
played by autonomic dysfunction. Kop et al. [21] examined
the relationship between measures of heart rate variability
(HRV), depressive symptoms as assessed by CES-D, and
cardiovascular mortality in a cohort of 907 participants
(59% women) without prior CHD. Of the 11 HRV indices
assessed, only one measure, daytime detrended fluctuation
analysis, was associated with depression. In addition, although depressive symptoms were associated with increased
cardiovascular mortality, addition of HRV and inflammatory
markers to the model only attenuated the association modestly (12.7%) [21]. On the other hand, an elegant study by
Way et al. [22] showed that a polymorphism in the promoter
region of the serotonin transporter gene SLC6A4 influenced
blood pressure and HRV in response to negative evaluations
in healthy young adults. The effect was moderated by sex
and was mainly seen in women [22]. This interesting finding
will need to be replicated, and further studies will need to
confirm whether SLC6A4 polymorphism and its downstream effect on autonomic function contribute to the relationship between depression and cardiovascular risk.
In contrast to the negative findings above, several studies
demonstrated that subclinical atherosclerosis may explain
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part of the association between depression and CHD risk.
Pizzi et al. [23] followed a cohort of 391 subjects (51%
women) with at least two CHD risk factors, and reported
that depressive symptoms defined as BDI score≥10 were
independently associated with increased carotid intimamedia thickening (CIMT) [23]. Similarly, Janssen et al.
[24] assessed the progression of coronary artery calcification (CAC) in 346 middle-aged women with no prior CHD
over an average of 2.3 years, showing that each standard
deviation increase in CES-D carried a 25% increased risk of
CAC progression. A study from Hamer et al. [25] followed
454 participants (46% women) from the Whitehall II cohort
and found that persistent depressive symptoms, defined as
General Health Questionnaire score≥4 on at least two occasions, was associated with increased risk of having CAC>0
and≥100 (OR 2.56, 95% CI 1.14–5.78 and OR 2.36, 95%
CI 1.04–5.35, respectively). However, in analysis stratified
by sex, this relationship was significant only in men, which
the authors attribute to decreased power due to the lower
prevalence of CAC in the women studied [25]. To assess the
direction of causality between depression and atherosclerosis, Newson et al. [26] analyzed data from 3564 participants
(56% female) enrolled in the Rotterdam study. They found
that baseline atherosclerosis, measured through CAC,
CIMT, aortic calcification, and ankle-brachial index, did
not predict incident depression [26]. As the authors note,
this result argues against atherosclerosis as a cause of depression, but is consistent with either depression leading to
an increase in cardiovascular risk or with both depression
and CHD being associated with other shared risk factors.
Two other studies that investigated novel mechanisms
linking depression and CHD in women deserve mentioning.
Hoen et al. [27] reported from the Heart and Soul Study that
in patients with CHD, shorter telomere length at baseline,
thought to be a potential marker for lifetime burden of
oxidative stress, was associated with depression. In a cohort
of 243 men and 139 women who had myocardial infarction,
Whang et al. [28] reported that BDI score≥10 was associated with significantly longer corrected QT interval in women (435.4±26.6 ms vs 408.6±24.3 ms) but not in men. The
authors suggest that this may help explain the known increased risk of sudden death and ventricular arrhythmia in
women with depression [28]. These findings will need to be
confirmed in other cohorts, but offer intriguing insights into
other potential biological mechanisms that may be involved
in the association between depression and cardiovascular
risk in women with CHD.
Social and Behavioral Mechanisms
Recently, considerable progress was made in our understanding of potential social and behavioral mechanisms that
link depression to CHD risk. In the Heart and Soul Study, it
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was shown that physical inactivity and smoking status
explained much of the association between depression and
recurrent cardiovascular events in patients with established
CHD [12•]. A similar finding was reported by Win et al.
[29], who followed 5888 elderly participants (58% female)
of the Cardiovascular Health Study over an average of
10.3 years. In this study, a low level of physical activity
predicted depression defined as CES-D score≥8; furthermore, although both depression and low level of physical
activity were associated with increased cardiovascular mortality, after adding physical activity to the model the log
hazard ratio for depression was reduced by 28% [29]. Our
group examined the relationship between physical inactivity, depressive symptoms, and subsequent cardiovascular
events or mortality in 4676 participants (40% women) with
prior CHD in the Reasons for Geographic and Racial Differences in Stroke Study and found a similar 21% reduction in
the association between depressive symptoms and clinical
events after accounting for physical inactivity (Ye et al.,
submitted). Taken together, it appears that physical inactivity is a powerful risk marker in this population, and whether
interventions that encourage exercise uptake in depressed
patients with CHD may be of benefit warrants further
investigation.
Several other studies reported on differential risks conveyed through component domains of depressive symptoms
in patients with CHD, highlighting the heterogeneity and
prognostic significance of possible depression phenotypes
[15•]. In a cohort of 453 patients hospitalized for acute coronary syndromes (ACS), of which 42% were women, we found
that anhedonia (the loss of pleasure or interest and one of the
two cardinal symptoms of depression) assessed by structured
interview was a stronger predictor of death or recurrent MI
(HR 1.58, 95% CI 1.16–2.14) than the presence of depressed
mood (the other cardinal symptom of depression) or major
depressive episodes [30]. Another report from the Heart and
Soul Study by Hoen et al. [31] showed that after full adjustment, only somatic symptoms, such as fatigue and difficulty
sleeping, were associated with increased risk for cardiovascular events (HR 1.14, 95% CI 1.05–1.24, for each somatic
symptom) in patients with prior CHD, whereas cognitive
symptoms such as depressed mood were not. This finding
was corroborated by a retrospective analysis of 2442 (44%
women) participants with depression or low perceived social
support enrolled in the Enhancing Recovery in Coronary
Heart Disease (ENRICHD) trial, which showed that at
12 months after the index MI, somatic symptoms but not
cognitive symptoms assessed by BDI were independently
associated with all-cause and cardiovascular mortality (HR
1.43, 95% CI 1.13–1.81 and HR 1.60, 95% CI 1.17–2.18,
respectively) [32]. As Hoen et al. [31] note, it is possible that
physical inactivity is related to the presence of somatic symptoms, thereby driving an increase in cardiovascular risk.
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There were also two reports that focused on increased
social vulnerabilities experienced by women with CHD and
comorbid depression. A study by Leifheit-Limson et al. [33]
showed that in a cohort of 2411 patients (33% women)
hospitalized for MI, low perceived social support was associated with significantly lower quality of life, physical functioning, and increased depressive symptoms. In sexstratified analysis, the effect was seen only in women and
not in men [33]. Similarly, in a cross-sectional study of 1951
patients (35% women) with CHD and depressive symptoms
measured by the Multiple Adjective Affect Checklist, Doering et al. [34] found that compared with men, women were
more likely to be single, to be unemployed, to have lower
level of education, and to perceive lower control over health.
These findings suggest that the increased social vulnerabilities
faced by women with CHD and comorbid depression may
represent another mechanism by which depression increases
cardiovascular risk in this patient population.

Diagnosis and Screening
As mentioned previously, depression screening has been
recommended for patients with CHD in both the 2008
AHA Science Advisory on Depression and Heart Disease
[5••] and the 2011 update of the AHA Practice Guidelines
for Prevention of Cardiovascular Disease in Women [6].
The AHA Advisory recommends administering a standard
depression screening questionnaire to patients with CHD,
with referral for those who screen positive to a professional
qualified to diagnose and manage depression. It is suggested
that the brief 2-item Patient Health Questionnaire (Table 1)
be used as the initial step, to be followed by the full 9-item
questionnaire if the initial screen is positive (Table 2), with
the acknowledgement that any standardized, valid depression questionnaire can be used in substitution [5••]. The
validity of the AHA Advisory algorithm (Fig. 1) is supported by a study from Elderon et al. [35] that evaluated the
algorithm’s performance in the Heart and Soul Study, and
showed that the algorithm was highly specific (0.91, 95% CI
0.89–0.93) though not sensitive (0.52, 95% CI 0.46–0.59).
Furthermore, after multivariate adjustment, those who
screened positive had elevated risk of adverse cardiovascular events (HR 1.41, 95% CI 1.10–1.81) [35].
Since the release of the AHA Advisory, several studies
have examined implementation of depression screening programs in patients with CHD. One study by Shemesh et al.
[36•] screened 1008 patients (~38% women) with CHD
using the algorithm suggested by the AHA Advisory and
found that 12% of those screened endorsed suicidal ideation
as assessed by question 9 on the PHQ-9; 121 patients had to
be interviewed immediately for safety, and after further
evaluation by a psychiatrist, 4 patients (0.45%) required
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Table 1 2-item Patient Health Questionnaire (PHQ-2)*, for initial
depression screening in patients with CHD
Over the past 2 weeks, how often have you been bothered by any of
the following problems?
(1) Little interest or pleasure in doing things.
(2) Feeling down, depressed, or hopeless.
*Answering “yes” to either question is considered screening positive,
and indicates need for further screening with PHQ-9, or for referral for
professional evaluation for depression diagnosis and treatment
(Adapted from Kroenke et al. [44]; with permission.)

hospitalization for suicidal intent [36•]. The study demonstrates a clear need of any screening program to put in place
appropriate and timely referral mechanisms for high-risk
patients. An interesting study by Smolderen et al. [37]
evaluated a single-center initiative mandating the nursing
staff to screen depression in patients hospitalized with MI
using the AHA Advisory algorithm. The performance of the
initiative was compared with depression assessment conducted separately through a large registry of which the
center was a member. Despite the initiative, 135 (26.8%)
of 503 eligible patients were not screened, and the proportion of women in the unscreened group was significantly
higher than those in the screened group (36.3% vs 26.6%,
P00.04). Furthermore, of patients who were identified as
having depression in the registry, only 38.3% were recognized through the screening initiative [37]. The authors’
experiences suggest that future efforts to implement depression screening programs in patients with CHD will need to
address the optimal mode of screening and potential barriers
in subgroups such as women.
Despite the AHA recommendations, however, the important issue of which instrument is the most suitable for
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depression assessment in patients with CHD remains unresolved. Viewveg et al. [38] points out in a recent review that
the various depression instruments used in cardiovascular
studies are highly heterogeneous and are derived from different patient populations. They were also frequently applied in settings that do not match those from which they
were developed and were scored using different cutoff values depending on the study. This heterogeneity limits comparison and generalizability of findings in this area [38], and
the diagnostic validity and clinical applicability of different
depression instruments will need to be investigated further.

Management
A recently released Cochrane review summarized the existing literature on pharmacologic and psychological interventions for depression in patients with CHD, concluding that
in general, interventions of either kind had no beneficial
effects on cardiovascular events or mortality, though there
may be a modest improvement in psychosocial dimensions
of quality of life assessment [8••]. The psychological interventions employed in the studies reviewed were Cognitive
Behavioral Therapy, Psychodynamic Psychotherapy, Interpersonal Psychotherapy, and Non-directive Supportive
Therapy and Counseling. Various commonly used antidepressants, particularly SSRIs, were considered in studies
of pharmacologic interventions. A reduction in hospitalizations was seen for pharmacologic intervention, but was
primarily driven by results from a single study, the Sertraline
Antidepressant Heart Attack Randomized Trial, which compared sertraline with placebo [39]. The Cochrane review
was not able to assess whether depression interventions
had differential effects on men and women. However, it

Table 2 Patient Health Questionnaire-9 (PHQ-9)* scale for depression screening
Over the past 2 weeks, how often have you been bothered by any of the following problems?
(1) Little interest or pleasure in doing things.
(2) Feeling down, depressed, or hopeless.
(3)
(4)
(5)
(6)
(7)
(8)

Trouble falling asleep, staying asleep, or sleeping too much.
Feeling tired or having little energy.
Poor appetite or overeating.
Feeling bad about yourself, feeling that you are a failure, or feeling that you have let yourself or your family down.
Trouble concentrating on things such as reading the newspaper or watching television.
Moving or speaking so slowly that other people would have noticed. Or being so fidgety or restless that you have
been moving around a lot more than usual.
(9) Thinking that you would be better off dead or that you want to hurt yourself in some way.
*For each question, “not at all” is scored as 0; “several days” as 1; “more than half of the days” as 2; and “nearly every day as 3”. Scores for all
items are summed to obtain total score for depression severity
(Adapted from Kroenke et al. [44]; with permission.)
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should be noted that in both the ENRICHD trial, which
compared cognitive behavioral therapy with sertraline versus usual care for severely depressed patients with CHD,
and the Montreal Heart Attack Readjustment Trial, which
evaluated home-based treatment of psychological stress
versus usual care, a trend towards increased MI or death
with intervention was seen in women only [7, 40]. These
two trials were among the largest conducted examining
depression treatment for CHD patients, and their findings
point to the need for careful assessment of the unique risk
profiles of women with CHD and comorbid depression that

may lead them to respond adversely to standardized depression
interventions.
Despite these negative findings, there were also several
recent trials of innovative depression treatment approaches
that seem promising. A large, primary care-based randomized clinical trial by Katon et al. [41•] evaluated the effect of
collaborative care—a team-based approach that combined
self-care support with pharmacotherapy and emphasized
individualized goal setting—in patients with depression
and either diabetes or CHD. The study enrolled 214 participants (52% women) and showed that after a 12-month

Fig. 1 Recommendation for depression screening from the 2008 American Heart Association Science Advisory on Depression and Heart Disease.
Asterisk indicates meets diagnostic criteria for major depression, has a
Patient Health Questionnaire (PHQ)-9 score of 10–19, has had no more
than 1 or 2 prior episodes of depression, and screens negative for bipolar
disorder, suicidality, significant substance abuse, or other major psychiatric
problems. Dagger indicates meets the diagnostic criteria for major depression and 1) has a PHQ-9 score ≥20; or 2) has had 3 or more prior depressive

episodes; or 3) screens positive for bipolar disorder, suicidality, significant
substance abuse, or other major psychiatric problem. Double dagger indicates that if “Yes” to Q.9 “suicidal,” immediately evaluate for acute
suicidality. If safe, refer for more comprehensive clinical evaluation; if at
risk for suicide, escort the patient to the emergency department. (Reprinted
from Lichtman JH, Bigger JT, Blumenthal JA, et al. [5••]. Depression and
Coronary Heart Disease. Circulation. 2008;118(17):1768–75; with
permission.)
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period, those who received intervention had significantly
improved depressive symptoms measured by the Symptom
Checklist-20 (difference, -0.40, 95% CI −0.56 to −0.26) as
well as improved control of hypertension, hyperlipidemia,
and diabetes [41•]. A similar study of collaborative care by
Huffman et al. [42] enrolled 175 patients with depression
(51% women) who were hospitalized for MI, arrhythmia, or
heart failure and found that compared with the usual care
arm, the intervention arm showed improved depressive
symptoms assessed by PHQ-9 at 12 weeks as well as the
number and severity of cardiac symptoms at 6 months.
However, no difference was seen in the number of cardiac
readmissions, and the effect of intervention on depressive
symptoms diminished after the end of the intervention period [42]. Similarly, our group recently reported findings from
the Coronary Psychosocial Evaluation Studies Randomized
Trial, which randomized 157 patients (54% women) with
persistent depressive symptoms following hospitalization
for ACS to usual care or an intervention comprised of
patient-preference driven problem solving therapy and/or
pharmacotherapy. At the end of the 6-month intervention
period, patients randomized to intervention had significantly
larger decrease in BDI score (difference, -1.9 points, 95%
CI −3.8 to −0.1) as well as decreased number of cardiac events
including death and recurrent ACS [43]. However, the effect
of intervention on cardiac events disappeared at 18-months of
follow-up, with analysis showing a significant group-time
interaction that suggested a “delayed risk” phenomenon after
the intervention ended (HR for intervention arm for the entire
follow-up period 0.94, 95% CI 0.44–2.04; HR for 6-month
treatment period 0.27, 95% CI 0.07–0.98; HR for after treatment period ended 4.07, 95% CI 0.84–19.73; P00.005 for
interaction) (Ye et al., submitted). We hypothesize that depression may need to be treated as a chronic disease, and that
providing depression treatment for short periods of time, and
then withdrawing it, may not be an appropriate strategy for
those with persistent depression.
Taken together, these results indicate that larger trials are
needed to detect whether these stepped depression interventions can improve quality of life and reduce the excess
cardiac risk in patients with CHD and comorbid depression.
An adequate number of women will need to be enrolled to
better delineate sex-specific risks and differences in response to intervention compared to men. Furthermore, our
experience suggests that the optimal timing and intensity of
depression treatment will need to be considered carefully,
and it may be that ongoing treatment is needed for the
benefit to persist, consistent with a conceptual model of
depression as a chronic illness. In the meantime, given the
absence of definitive data, it is reasonable to offer continued
psychological and/or pharmacologic treatment of depression
in patients with CHD based on individual preference, an
approach that has been shown to be associated with high
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patient satisfaction and significant depression improvement
[30, 43].

Conclusions
In this review, we summarized recent findings on the high
prevalence of depression in women with CHD and its association with increased risk for adverse cardiovascular events
and mortality. A number of studies suggested that this
association may be explained in part by biological mechanisms such as endothelial dysfunction, subclinical atherosclerosis, inflammation, and autonomic dysregulation,
though the current data suggest that they do not explain
the majority of the association. In contrast, social and behavioral mechanisms such as physical inactivity and decreased level of social support are increasingly being
shown to play an important role in the relationship between
depression and cardiovascular risk, particularly in women.
Despite recommendations for universal screening of depression in patients with CHD, implementation of screening
guidelines remains a challenge, and screening may be less
likely to occur in women as compared to men. Unfortunately, psychological and pharmacologic interventions of depression in patients with CHD have thus far shown only
limited benefit with regards to cardiac outcomes, though
new models of collaborative, personalized care hold promise.
Future research is needed to clarify the mechanisms that
underlie sex-specific differences in depression and cardiovascular risk and to identify effective strategies of depression
management that also reduce cardiovascular morbidity and
mortality.
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